Alirocumab in Patients on a Stable Dialysis Regimen
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
12-week study of the efficacy and safety of alirocumab in patients maintained stably on
hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9
levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at
weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.